These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 20356491)

  • 21. Phase I-II study of gemcitabine and carboplatin in stage IIIB-IV non-small-cell lung cancer.
    Iaffaioli RV; Tortoriello A; Facchini G; Caponigro F; Gentile M; Marzano N; Gravina A; Dimitri P; Costagliola G; Ferraro A; Ferrante G; De Marino V; Illiano A
    J Clin Oncol; 1999 Mar; 17(3):921-6. PubMed ID: 10071285
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Phase II study of first-line sequential chemotherapy with gemcitabine-carboplatin followed by docetaxel in patients with advanced non-small cell lung cancer.
    Chiappori A; Simon G; Williams C; Haura E; Rocha-Lima C; Wagner H; Bepler G; Antonia S
    Oncology; 2005; 68(4-6):382-90. PubMed ID: 16020967
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Gemcitabine versus gemcitabine/carboplatin in advanced non-small cell lung cancer: preliminary findings in a phase III trial of the Swedish Lung Cancer Study Group.
    Sederholm C
    Semin Oncol; 2002 Jun; 29(3 Suppl 9):50-4. PubMed ID: 12094340
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Gemcitabine and carboplatin in patients with locally advanced or metastatic non-small cell lung cancer: a prospective phase II study.
    Kortsik C; Albrecht P; Elmer A
    Lung Cancer; 2003 Apr; 40(1):85-90. PubMed ID: 12660012
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Clinical efficacy and adverse effects of taxol plus carboplatin or gemcitabine plus carboplatin in patients with advanced non-small-cell lung carcinoma].
    Wang XY; Zhao YL
    Zhonghua Yi Xue Za Zhi; 2010 Dec; 90(47):3362-4. PubMed ID: 21223755
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Gemcitabine/carboplatin in patients with metastatic non-small-cell lung cancer: phase II study of 28-day and 21-day schedules.
    Obasaju CK; Ye Z; Bloss LP; Monberg MJ; Curiel RE
    Clin Lung Cancer; 2005 Nov; 7(3):202-7. PubMed ID: 16354316
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Phase II multicenter trial with carboplatin and gemcitabine induction chemotherapy followed by radiotherapy concomitantly with low-dose paclitaxel and gemcitabine for stage IIIA and IIIB non-small cell lung cancer.
    Hirsh V; Soulieres D; Duclos M; Faria S; Del Vecchio P; Ofiara L; Ayoub JP; Charpentier D; Gruber J; Portelance L; Souhami L
    J Thorac Oncol; 2007 Oct; 2(10):927-32. PubMed ID: 17909355
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A randomized phase II trial of pemetrexed/gemcitabine/bevacizumab or pemetrexed/carboplatin/bevacizumab in the first-line treatment of elderly patients with advanced non-small cell lung cancer.
    Spigel DR; Hainsworth JD; Shipley DL; Ervin TJ; Kohler PC; Lubiner ET; Peyton JD; Waterhouse DM; Burris HA; Greco FA
    J Thorac Oncol; 2012 Jan; 7(1):196-202. PubMed ID: 21900836
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparative effectiveness of three platinum-doublet chemotherapy regimens in elderly patients with advanced non-small cell lung cancer.
    Zhu J; Sharma DB; Chen AB; Johnson BE; Weeks JC; Schrag D
    Cancer; 2013 Jun; 119(11):2048-60. PubMed ID: 23564469
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Randomized Phase II trial of paclitaxel and carboplatin followed by gemcitabine switch-maintenance therapy versus gemcitabine and carboplatin followed by gemcitabine continuation-maintenance therapy in previously untreated advanced non-small cell lung cancer.
    Minami S; Kijima T; Shiroyama T; Okafuji K; Hirashima T; Uchida J; Imamura F; Osaki T; Nakatani T; Ogata Y; Yamamoto S; Namba Y; Otsuka T; Tachibana I; Komuta K; Kawase I
    BMC Res Notes; 2013 Jan; 6():3. PubMed ID: 23281805
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Gemcitabine (GEM) and carboplatin (CBDCA) versus cisplatin (CDDP) and vinblastine (VLB) in advanced non-small-cell lung cancer (NSCLC) stages III and IV: a phase III randomised trial.
    Grigorescu AC; Draghici IN; Nitipir C; Gutulescu N; Corlan E
    Lung Cancer; 2002 Jul; 37(1):9-14. PubMed ID: 12057861
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Paclitaxel plus carboplatin, compared with paclitaxel plus gemcitabine, shows similar efficacy while more cost-effective: a randomized phase II study of combination chemotherapy against inoperable non-small-cell lung cancer previously untreated.
    Chen YM; Perng RP; Lee YC; Shih JF; Lee CS; Tsai CM; Whang-Peng J
    Ann Oncol; 2002 Jan; 13(1):108-15. PubMed ID: 11863090
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Randomized phase II study of carboplatin/gemcitabine versus vinorelbine/gemcitabine in patients with advanced nonsmall cell lung cancer: West Japan Thoracic Oncology Group (WJTOG) 0104.
    Yamamoto N; Nakagawa K; Uejima H; Sugiura T; Takada Y; Negoro S; Matsui K; Kashii T; Takada M; Nakanishi Y; Kato T; Fukuoka M;
    Cancer; 2006 Aug; 107(3):599-605. PubMed ID: 16804877
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Gemcitabine and low dose carboplatin in the treatment of elderly patients with advanced non-small cell lung cancer.
    Maestu I; Gómez-Aldaraví L; Torregrosa MD; Camps C; Llorca C; Bosch C; Gómez J; Giner V; Oltra A; Albert A
    Lung Cancer; 2003 Dec; 42(3):345-54. PubMed ID: 14644523
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A phase II trial of carboplatin and gemcitabine with exisulind (IND #65,056) in patients with advanced non-small cell lung cancer: an Eastern Cooperative Oncology Group study (E1501).
    Masters GA; Li S; Dowlati A; Madajewicz S; Langer C; Schiller J; Johnson D
    J Thorac Oncol; 2006 Sep; 1(7):673-8. PubMed ID: 17409935
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Prospective phase II trial of a combination of gemcitabine and UFT as first-line treatment in elderly patients with advanced non-small cell lung cancer.
    Baek JH; Kim H; Ahn JJ; Jegal Y; Seo KW; Ra SW; Park CR; Jung JP; Kim JW; Lee YJ; Cha HJ; Kwon WJ; Noh YJ; Oh S; Park JH; Min YJ
    Lung Cancer; 2012 Jun; 76(3):368-72. PubMed ID: 22192919
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A phase II, open-label trial of bortezomib (VELCADE(®)) in combination with gemcitabine and cisplatin in patients with locally advanced or metastatic non-small cell lung cancer.
    Kontopodis E; Kotsakis A; Kentepozidis N; Syrigos K; Ziras N; Moutsos M; Filippa G; Mala A; Vamvakas L; Mavroudis D; Georgoulias V; Agelaki S
    Cancer Chemother Pharmacol; 2016 May; 77(5):949-56. PubMed ID: 26994909
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A phase III randomized trial of gemcitabine-oxaliplatin versus carboplatin-paclitaxel as first-line therapy in patients with advanced non-small cell lung cancer.
    Weissman CH; Reynolds CH; Neubauer MA; Pritchard S; Kobina S; Asmar L
    J Thorac Oncol; 2011 Feb; 6(2):358-64. PubMed ID: 21206386
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Phase II study of PKC-alpha antisense oligonucleotide aprinocarsen in combination with gemcitabine and carboplatin in patients with advanced non-small cell lung cancer.
    Ritch P; Rudin CM; Bitran JD; Edelman MJ; Makalinao A; Irwin D; Lilenbaum R; Peterson P; John WJ
    Lung Cancer; 2006 May; 52(2):173-80. PubMed ID: 16507327
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Gemcitabine, paclitaxel, and carboplatin for advanced non-small-cell lung cancer.
    Greco FA; Burris HA; Hainsworth JD
    Oncology (Williston Park); 2000 Jul; 14(7 Suppl 4):31-4. PubMed ID: 10960943
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.